Concepedia

Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in <i>HER-2/neu</i>–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401

Minna Tanner, Jorma Isola, Tom Wiklund, Björn Erikstein, Pirkko Kellokumpu‐Lehtinen, Per Malmström, Nils Wilking, Jonas Nilsson, Jonas Bergh

Journal of Clinical Oncology · 2006 · 255 citations · 28 references

DOIFull text

Open access

Abstract

Coamplification of HER-2/neu and TOP2A may define a subgroup of high-risk breast cancer patients who benefit from individually tailored and dose-escalated adjuvant anthracyclines.

References

28

Partial residuals for the proportional hazards regression model

David Schoenfeld · Biometrika · 1982 · 2.9K citations

, , +16

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

D. Craig Allred, Jennet Harvey, Melora D. Berardo et al. · PubMed · 1998 · 2.2K citations

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

I. Craig Henderson, Donald A. Berry, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 1.3K citations

Treatment of Breast Cancer

Gabriel N. Hortobágyi · New England Journal of Medicine · 1998 · 779 citations

, , +13

erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

Soonmyung Paik, John Bryant, Chanheun Park et al. · JNCI Journal of the National Cancer Institute · 1998 · 653 citations